Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference
Ultragenyx Pharmaceutical, a biopharmaceutical firm focused on rare genetic diseases, announced that CEO Emil D. Kakkis will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx Pharmaceutical, a biopharmaceutical firm focused on rare genetic diseases, announced that CEO Emil D. Kakkis will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference. The presentation is scheduled for January 12, 2021, at 2:50 PM EST. The live webcast will be accessible from their website, with a replay available for 30 days. Ultragenyx aims to develop novel therapies to address high unmet medical needs in rare diseases, guided by an experienced management team dedicated to efficient drug development.
Details
News Market Reaction – RARE
The recorded move for RARE in the trading session of this news was -1.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 12, 2021 at 2:50 pm EST.
The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 30 days.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-660-0951
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.